TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA

Insider Sentiment (TTM):

Last Purchase:2025-09-05Last Sale:2026-06-18Shares Purchased (TTM):1,113Shares Sold (TTM):3,017,298

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:550,760,244Shares Outstanding:1,156,000,000Institutional Ownership Pct.:47.64%

Earnings Market Reaction:

Filing Date:2026-07-29Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	3,655	3,741	3,556	2,203	2,161	1,697	3,300	3,319	2,258	2,991	3,226	2,249
Accounts Receivable Net Current	3,493	3,393	3,709	3,810	3,564	3,384	3,059	3,462	3,766	3,456	3,408	3,385
Inventory Net	3,221	3,176	3,179	3,323	3,497	3,247	3,007	3,959	3,927	3,949	4,021	4,051
Prepaid Expense Current	1,034	1,070	1,122	1,115	1,084	1,018	1,006	1,127	1,096	1,336	1,255	1,168
Other Assets Current	563	535	539	477	472	368	409	445	517	495	504	520
Assets Of Disposal Group Including Discontinued Op…	1,794	1,794	1,842	1,809	1,842	1,814	1,771	2	69	70	70	51
Assets Current	13,760	13,710	13,946	12,736	12,620	11,528	12,552	12,314	11,632	12,297	12,485	11,425
Deferred Income Tax Assets Net	2,162	2,190	2,191	1,634	1,781	1,762	1,799	2,070	2,000	1,960	1,812	1,755
Other Assets Noncurrent	387	377	405	444	470	464	462	459	434	470	470	477
Property Plant And Equipment Net	3,928	3,998	4,080	4,820	4,810	4,631	4,581	5,672	5,573	5,618	5,750	5,622
Operating Lease Right Of Use Asset	333	335	345	342	358	363	367	364	358	364	397	406
Finite Lived Intangible Assets Net	3,447	3,609	3,781	3,936	4,142	4,189	4,418	4,756	4,853	5,056	5,387	5,525
Goodwill	15,839	15,822	16,000	15,945	15,949	15,477	15,147	16,124	16,488	17,007	17,177	16,885
Assets	39,857	40,040	40,748	39,856	40,131	38,415	39,326	41,758	41,338	42,773	43,479	42,095
Liabilities And Stockhold…
Liabilities Current
Debt Current	4,500	2,612	1,820	24	464	421	1,781	2,580	2,094	3,060	1,672	1,479
Accounts Payable Trade Current	2,721	2,596	2,531	2,355	2,498	2,290	2,203	2,371	2,366	2,439	2,602	2,280
Employee Related Liabilities Current	488	555	739	561	481	474	624	619	492	492	611	530
Other Liabilities Current	987	1,111	1,182	1,103	940	964	1,020	1,241	1,191	1,161	1,044	1,011
Liabilities Current	15,646	13,532	13,456	11,491	11,861	11,157	12,796	13,797	13,037	13,792	12,247	11,394
Liabilities Noncurrent
Deferred Tax And Other Liabilities Noncurrent	289	273	296	399	440	461	483	538	553	569	606	544
Other Liabilities Noncurrent	3,791	3,709	3,808	3,664	3,938	4,011	4,028	4,344	4,356	3,991	4,019	3,950
Long Term Notes And Loans	12,092	14,015	14,986	16,766	16,763	16,230	16,002	16,400	16,547	16,584	18,161	18,495
Operating Lease Liability Noncurrent	282	280	288	283	296	288	296	295	281	294	320	324
Liabilities Noncurrent	16,454	18,277	19,379	21,111	21,436	20,990	20,809	21,578	21,737	21,438	23,106	23,314
Liabilities	32,100	31,809	32,834	32,602	33,297	32,146	33,606	35,375	34,774	35,230	35,353	34,708
Redeemable Noncontrolling Interest Equity Carrying…	-	-	0	0	0	0	340	-	-	-	0	-
Stockholders Equity
Common Stock Value	59	59	58	58	58	58	58	58	58	58	57	57
Additional Paid In Capital	28,256	28,203	28,133	28,038	28,003	27,965	27,764	27,860	27,829	27,796	27,807	27,780
Retained Earnings Accumulated Deficit	-13,969	-13,394	-13,762	-14,243	-14,676	-14,958	-15,173	-14,956	-14,519	-13,673	-13,534	-13,995
Accumulated Other Comprehensive Income Loss Net Of…	-2,465	-2,512	-2,391	-2,475	-2,431	-2,675	-3,148	-2,769	-2,881	-2,775	-2,697	-2,910
Treasury Stock Value	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128	-4,128
Stockholders Equity	7,753	8,228	7,910	7,254	6,827	6,269	5,373	6,383	6,563	7,543	8,126	7,387
Minority Interest	4	4	4	4	7	7	7	319	204	265	620	582
Liabilities And Stockholders Equity	39,857	40,040	40,748	39,856	40,131	38,415	39,326	41,758	41,338	42,773	43,479	42,095
Allowance For Doubtful Accounts Receivable Current	75	75	81	82	84	80	78	91	95	98	95	86
Common Stock Par Or Stated Value Per Share	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Common Stock Shares Authorized	2,495	2,495	2,495	2,495	2,495	2,495	2,495	2,495	2,495	2,495	2,495	2,495
Common Stock Shares Issued	1,271	1,271	1,257	1,253	1,253	1,253	1,240	1,240	1,239	1,238	1,227	1,227
Treasury Stock Common Shares	106	107	107	106	106	106	107	106	106	106	106	106

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-3.70%	-11.02%	-9.47%	-	-	-	-	-	-	-	-	-
2025	-4.66%	-4.77%	-6.02%	9.69%	9.03%	14.74%	9.31%	29.63%	29.31%	-6.59%	-20.72%	-15.48%
2024	7.56%	3.24%	8.64%	6.48%	0.46%	2.98%	-3.73%	30.64%	24.38%	-4.36%	-12.38%	-13.60%
2023	-	-	-	4.86%	11.89%	-12.22%	10.72%	19.04%	35.80%	5.50%	10.38%	8.29%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.88	1.01	1.04	1.11	1.06	1.03	0.98	0.89	0.89	0.89	1.02	1.00
Quick Ratio	0.61	0.70	0.72	0.72	0.68	0.65	0.67	0.52	0.51	0.51	0.59	0.54
Working Capital	-1.89B	178.00M	490.00M	1.25B	759.00M	371.00M	-244.00M	-1.48B	-1.41B	-1.50B	238.00M	31.00M
Leverage & Debt
Debt to Equity	4.14	3.87	4.15	4.49	4.88	5.13	6.25	5.54	5.30	4.67	4.35	4.70
Debt Ratio	0.81	0.79	0.81	0.82	0.83	0.84	0.85	0.85	0.84	0.82	0.81	0.82
Efficiency & Turnover
Asset Turnover TTM	0.43	0.44	0.43	0.41	0.41	0.41	0.40	0.40	0.39	0.37	0.36	0.35
Days Sales Outstanding TTM	74.38	71.29	71.57	79.11	80.45	75.13	71.34	74.50	81.84	78.58	81.82	85.02
Receivables Turnover TTM	4.91	5.12	5.10	4.61	4.54	4.86	5.12	4.90	4.46	4.64	4.46	4.29
Per Share Metrics
Diluted EPS TTM	0.61	1.33	1.22	0.34	-0.41	-1.38	-1.73	-0.82	-0.37	-0.40	-0.50	-2.06
Free Cash Flow Per Share TTM	1.16	1.01	1.00	0.50	0.78	0.67	0.66	1.21	0.60	0.78	0.75	0.54
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	52.46%	52.07%	51.79%	50.10%	49.60%	49.17%	48.74%	49.84%	49.49%	48.95%	48.25%	45.83%
Operating Profit Margin TTM	9.26%	13.20%	12.50%	10.89%	5.38%	2.61%	-1.83%	2.87%	5.38%	1.42%	2.73%	-8.36%
Net Profit Margin TTM	4.09%	9.03%	8.22%	2.37%	-2.84%	-9.63%	-11.84%	-5.56%	-2.57%	-2.78%	-3.53%	-15.31%
Growth Metrics
Net Revenue Growth (1Y)	4.13%	4.41%	4.32%	0.02%	2.07%	3.82%	4.40%	9.82%	8.48%	7.23%	6.17%	0.87%
Net Income Growth (1Y)	-250.21%	-197.94%	-172.38%	-142.66%	12.65%	259.55%	250.45%	-60.09%	-82.22%	-74.48%	-77.15%	80.82%
EPS Growth (1Y)	-247.89%	-196.41%	-171.50%	-142.14%	11.27%	254.81%	246.73%	-60.52%	-82.43%	-74.67%	-77.33%	79.21%
Valuation Metrics
P/E TTM	55.67	22.22	25.20	58.21	-40.73	-10.93	-12.72	-21.88	-43.94	-35.61	-20.90	-4.89
P/B TTM	5.09	4.23	4.52	3.19	2.82	2.79	4.63	3.20	2.81	2.10	1.44	1.55
P/S TTM	2.28	2.01	2.07	1.38	1.16	1.05	1.51	1.22	1.13	0.99	0.74	0.75
Market Cap	39.47B	34.82B	35.74B	23.17B	19.22B	17.49B	24.93B	20.42B	18.41B	15.85B	11.68B	11.43B
Enterprise Value	40.32B	33.69B	34.00B	20.99B	17.53B	16.22B	23.41B	19.68B	18.25B	15.91B	10.13B	10.66B
Calculated Values
Free Cash Flow TTM	1.35B	1.17B	1.15B	578.00M	890.00M	765.00M	749.00M	1.37B	679.00M	878.00M	842.00M	608.00M
Net Debt	845.00M	-1.13B	-1.74B	-2.18B	-1.70B	-1.28B	-1.52B	-739.00M	-164.00M	69.00M	-1.56B	-771.00M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-18Sale

Owner: Shields, Matthew

Title: EVP, Global Operations

Shares: 9,989

Price/Share: $32.19

Value: $321,545.91

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-06-11Sale

Owner: Kalif, Eliyahu Sharon

Title: EVP, Chief Financial Officer

Shares: 106,563

Price/Share: $34.10

Value: $3,633,798.30

Shares Owned: 65,621

Relationship: Officer

Ownership: Direct

2026-06-05Sale

Owner: Francis, Richard D

Title: President and CEO

Shares: 6,153

Price/Share: $34.35

Value: $211,355.55

Shares Owned: 1,177,529

Relationship: Officer

Ownership: Direct

2026-06-03Sale

Owner: Shields, Matthew

Title: EVP, Global Operations

Shares: 16,195

Price/Share: $32.87

Value: $532,329.65

Shares Owned: 9,989

Relationship: Officer

Ownership: Direct

2026-05-14Sale

Owner: Kalif, Eliyahu Sharon

Title: EVP, Chief Financial Officer

Shares: 153,251

Price/Share: $35.61

Value: $5,457,268.11

Shares Owned: 172,184

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-18	Shields, Matthew	Officer	EVP, Global Operations	Direct	Sale	9,989	32.19	$321,545.91	0	4
2026-06-11	Kalif, Eliyahu Sharon	Officer	EVP, Chief Financial Officer	Direct	Sale	106,563	34.10	$3,633,798.30	65,621	4
2026-06-05	Francis, Richard D	Officer	President and CEO	Direct	Sale	6,153	34.35	$211,355.55	1,177,529	4
2026-06-03	Shields, Matthew	Officer	EVP, Global Operations	Direct	Sale	16,195	32.87	$532,329.65	9,989	4
2026-05-14	Kalif, Eliyahu Sharon	Officer	EVP, Chief Financial Officer	Direct	Sale	153,251	35.61	$5,457,268.11	172,184	4
2026-05-14	Lippman, Evan	Officer	EVP, Business Development	Direct	Sale	41,658	35.58	$1,482,191.64	6,095	4
2026-05-06	Weiss, Amir	Officer	Chief Accounting Officer	Direct	Sale	10,679	36.00	$384,444.00	20,016	4
2026-05-05	Daniell, Richard	Officer	EVP, Europe Commercial	Direct	Sale	30,000	35.40	$1,062,000.00	55,755	4
2026-05-01	Sabag, Mark	Officer	See "Remarks"	Direct	Sale	144,180	34.99	$5,044,858.20	80,760	4
2026-04-30	Fox, Christine	Officer	EVP, U.S. Commercial	Direct	Sale	21,258	35.31	$750,619.98	63,647	4
2026-03-17	Sabag, Mark	Officer	See "Remarks"	Direct	Sale	62,102	30.14	$1,871,754.28	224,940	4
2026-03-05	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	9,533	31.67	$301,910.11	107,711	4
2026-03-05	Shields, Matthew	Officer	EVP, Global Operations	Direct	Sale	17,295	31.67	$547,732.65	9,989	4
2026-03-05	Fox, Christine	Officer	EVP, U.S. Commercial	Direct	Sale	7,924	31.67	$250,953.08	84,905	4
2026-03-05	Daniell, Richard	Officer	EVP, Europe Commercial	Direct	Sale	17,295	31.67	$547,732.65	85,755	4
2026-03-05	Francis, Richard D	Officer	President and CEO	Direct	Sale	20,025	31.67	$634,191.75	1,170,639	4
2026-03-05	Savage, Brian	Officer	Interim Chief Legal Officer	Direct	Sale	1,127	31.67	$35,692.09	10,914	4
2026-03-05	Jover, Placid	Officer	See "Remarks"	Direct	Sale	14,150	31.67	$448,130.50	6,774	4
2026-03-04	Savage, Brian	Officer	Interim Chief Legal Officer	Direct	Sale	2,675	32.46	$86,830.50	6,181	4
2026-03-04	Fox, Christine	Officer	EVP, U.S. Commercial	Direct	Sale	9,098	32.46	$295,321.08	75,010	4
2026-03-04	Francis, Richard D	Officer	President and CEO	Direct	Sale	23,393	32.46	$759,336.78	1,148,212	4
2026-03-04	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	11,277	32.46	$366,051.42	97,590	4
2026-03-04	Daniell, Richard	Officer	EVP, Europe Commercial	Direct	Sale	91,345	32.62	$2,979,673.90	85,755	4
2026-03-03	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	80,762	32.36	$2,613,458.32	12,823	4
2026-03-03	Savage, Brian	Officer	Interim Chief Legal Officer	Direct	Sale	1,274	32.36	$41,226.64	2,926	4
2026-03-03	Francis, Richard D	Officer	President and CEO	Direct	Sale	442,935	32.36	$14,333,376.60	642,099	4
2026-03-03	Daniell, Richard	Officer	EVP, Europe Commercial	Direct	Sale	128,985	32.36	$4,173,954.60	48,384	4
2026-02-26	Kalif, Eliyahu Sharon	Officer	EVP, Chief Financial Officer	Direct	Sale	345,810	33.64	$11,633,048.40	57,478	4
2026-02-15	Francis, Richard D	Officer	President and CEO	Direct	Sale	447,778	34.22	$15,322,963.16	271,783	4
2025-12-16	Mignone, Roberto	Director	-	Indirect	Sale	77,400	30.24	$2,340,576.00	367,600	4
2025-12-16	Weiss, Amir	Officer	Chief Accounting Officer	Direct	Sale	12,300	30.20	$371,460.00	5,650	4
2025-12-09	Sabag, Mark	Officer	See "Remarks"	Direct	Sale	216,892	28.72	$6,229,138.24	52,828	4
2025-12-09	Daniell, Richard	Officer	Exec. VP, European Commercial	Direct	Sale	115,468	28.68	$3,311,622.24	48,384	4
2025-11-26	Mignone, Roberto	Director	-	Indirect	Sale	50,000	26.03	$1,301,500.00	445,000	4
2025-11-20	Fox, Christine	Officer	EVP, Head of U.S. Commercial	Direct	Sale	28,229	24.78	$699,514.62	63,647	4
2025-11-14	Fox, Christine	Officer	EVP, Head of U.S. Commercial	Direct	Sale	30,000	25.11	$753,300.00	28,384	4
2025-11-06	Weiss, Amir	Officer	Chief Accounting Officer	Direct	Sale	12,300	24.44	$300,612.00	17,950	4
2025-11-06	Mignone, Roberto	Director	-	Indirect	Sale	200,000	24.11	$4,822,000.00	495,000	4
2025-09-05	Mcavoy, David R.	Officer	EVP, Chief Legal Officer	Direct	Purchase	1,113	18.86	$20,991.18	13,027	4
2025-08-01	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	52,742	15.16	$799,568.72	0	4
2025-08-01	Jover, Placid	Officer	See "Remarks"	Direct	Sale	6,053	15.16	$91,763.48	6,774	4
2025-06-12	Kalif, Eliyahu Sharon	Officer	EVP, Chief Financial Officer	Direct	Sale	55,775	17.08	$952,637.00	403,288	4
2025-06-03	Shields, Matthew	Officer	EVP, Global Operations	Direct	Sale	6,206	17.02	$105,626.12	9,989	4
2025-05-08	Sabag, Mark	Officer	See "Remarks"	Direct	Sale	337,915	18.04	$6,095,986.60	150,996	4
2025-03-05	Francis, Richard D	Officer	President and CEO	Direct	Sale	8,259	15.91	$131,400.69	271,783	4
2025-03-05	Fox, Christine	Officer	EVP, Head of U.S. Commercial	Direct	Sale	2,147	15.91	$34,158.77	58,384	4
2025-03-05	Daniell, Richard	Officer	Exec. VP, European Commercial	Direct	Sale	70,961	15.90	$1,128,279.90	48,384	4
2025-03-05	Mcavoy, David R.	Officer	EVP, Chief Legal Officer	Direct	Sale	1,677	15.91	$26,681.07	11,914	4
2025-03-05	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	8,077	15.91	$128,505.07	0	4
2025-03-04	Daniell, Richard	Officer	Exec. VP, European Commercial	Direct	Sale	91,608	15.73	$1,440,993.84	7,108	4
2025-03-03	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	19,726	16.19	$319,363.94	5,174	4
2025-03-03	Francis, Richard D	Officer	President and CEO	Direct	Sale	24,892	16.19	$403,001.48	251,783	4
2025-03-03	Daniell, Richard	Officer	Exec. VP, European Commercial	Direct	Sale	49,314	16.19	$798,393.66	12,936	4
2025-02-28	Kalif, Eliyahu Sharon	Officer	EVP, Chief Financial Officer	Direct	Sale	55,750	16.21	$903,707.50	147,941	4
2025-02-18	Francis, Richard D	Officer	President and CEO	Direct	Sale	75,506	16.95	$1,279,826.70	209,444	4
2025-02-12	Sabag, Mark	Officer	See "Remarks"	Direct	Sale	177,626	16.25	$2,886,422.50	204,964	4
2024-12-20	Mignone, Roberto	Director	-	Indirect	Sale	286,000	22.01	$6,294,860.00	695,000	4
2024-11-20	Fox, Christine	Officer	EVP, Head of U.S. Commercial	Direct	Sale	19,388	16.87	$327,075.56	44,104	4
2024-08-12	Daniell, Richard	Officer	Exec. VP, European Commercial	Direct	Sale	98,943	17.30	$1,711,713.90	0	4
2024-08-09	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	45,060	17.38	$783,142.80	0	4
2024-08-09	Grant, Angus	Officer	EVP, Business Development	Direct	Sale	4,065	17.28	$70,243.20	8,848	4
2024-08-01	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	24,537	17.25	$423,263.25	45,060	4
2024-06-18	Mignone, Roberto	Director	-	Indirect	Sale	519,000	17.03	$8,838,570.00	981,000	4
2024-05-16	Weiss, Amir	Officer	Chief Accounting Officer	Direct	Sale	12,635	16.65	$210,372.75	5,179	4
2024-05-13	Conway, Vikki L	Officer	See "Remarks"	Direct	Sale	15,219	16.74	$254,766.06	0	4
2024-03-06	Kalif, Eliyahu Sharon	Officer	EVP, Chief Financial Officer	Direct	Sale	77,550	13.52	$1,048,476.00	203,691	4
2024-03-05	Conway, Vikki L	Officer	See "Remarks"	Direct	Sale	1,427	13.52	$19,293.04	15,219	4
2024-03-05	Sabag, Mark	Officer	EVP, International Markets	Direct	Sale	100,000	13.52	$1,352,000.00	382,590	4
2024-03-05	Daniell, Richard	Officer	Exec. VP, European Commercial	Direct	Sale	48,629	13.52	$657,464.08	69,770	4
2024-03-04	Francis, Richard D	Officer	President and CEO	Direct	Sale	31,061	13.34	$414,353.74	123,295	4
2024-03-04	Conway, Vikki L	Officer	See "Remarks"	Direct	Sale	3,532	13.37	$47,222.84	6,617	4
2024-03-04	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	8,045	13.34	$107,320.30	16,855	4
2024-03-04	Daniell, Richard	Officer	Exec. VP, European Commercial	Direct	Sale	95,762	13.34	$1,277,465.08	69,770	4
2024-02-28	Drape, Eric	Officer	Executive VP Global Operations	Direct	Sale	9,815	13.12	$128,772.80	9,701	4
2024-02-28	Conway, Vikki L	Officer	See "Remarks"	Direct	Sale	1,366	13.12	$17,921.92	2,928	4
2024-02-28	Daniell, Richard	Officer	Exec. VP, European Commercial	Direct	Sale	20,599	13.12	$270,258.88	69,770	4
2024-02-16	Drape, Eric	Officer	Executive VP Global Operations	Direct	Sale	173,261	13.05	$2,261,056.05	1	4
2024-02-15	Francis, Richard D	Officer	President and CEO	Direct	Sale	74,530	13.15	$980,069.50	87,125	4
2024-02-01	Weiss, Amir	Officer	Chief Accounting Officer	Direct	Sale	31,766	12.37	$392,945.42	10,676	4
2023-08-07	Kalif, Eliyahu Sharon	Officer	EVP, Chief Financial Officer	Direct	Sale	35,125	9.73	$341,766.25	99,162	4
2023-08-04	Weiss, Amir	Officer	Chief Accounting Officer	Direct	Sale	1,981	9.92	$19,655.59	42,442	4
2023-08-01	Hughes, Eric A	Officer	See "Remarks"	Direct	Sale	52,742	8.30	$437,758.60	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

47.64%

Inst. Shares: 550,760,244

Shares Outstanding: 1,156,000,000

2025-12-31

46.62%

Inst. Shares: 533,814,049

Shares Outstanding: 1,145,000,000

2025-09-30

45.16%

Inst. Shares: 518,012,381

Shares Outstanding: 1,147,000,000

2025-06-30

50.55%

Inst. Shares: 579,810,486

Shares Outstanding: 1,147,000,000

2025-03-31

52.15%

Inst. Shares: 593,485,494

Shares Outstanding: 1,138,000,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	550,760,244	1,156,000,000	47.64%
2025-12-31	533,814,049	1,145,000,000	46.62%
2025-09-30	518,012,381	1,147,000,000	45.16%
2025-06-30	579,810,486	1,147,000,000	50.55%
2025-03-31	593,485,494	1,138,000,000	52.15%
2024-12-31	585,937,626	1,131,000,000	51.81%
2024-09-30	548,096,368	1,133,000,000	48.38%
2024-06-30	520,033,538	1,133,000,000	45.90%
2024-03-31	485,443,946	1,123,000,000	43.23%
2023-12-31	465,042,602	1,119,000,000	41.56%
2023-09-30	394,111,372	1,121,000,000	35.16%
2023-06-30	366,061,295	1,120,000,000	32.68%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) — SEC Financial Statements & Analysis

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is a pharmaceutical preparations company, incorporated in L3. TEVA PHARMACEUTICAL INDUSTRIES LTD trades on NYSE, OTC as: TEVA, TEVJF. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), TEVA PHARMACEUTICAL INDUSTRIES LTD reported a 4.13% year-over-year revenue growth, a Gross Profit Margin of 52.46% (TTM), a Debt-to-Equity ratio of 4.14x, a Price-to-Sales (P/S) ratio of 2.28x (TTM), a Price-to-Book (P/B) ratio of 5.09x (TTM), at a market cap of $39.47B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 4.13%
Gross Profit Margin TTM: 52.46%
Debt To Equity: 4.14x
P/S TTM: 2.28x
P/B TTM: 5.09x
Market Cap: $39.47B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is TEVA PHARMACEUTICAL INDUSTRIES LTD in?

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) operates in the Pharmaceutical Preparations industry.

What is TEVA's market cap?

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a market capitalization of $39.47B as of 2026-06-30.

What is TEVA's P/E ratio?

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s trailing twelve month P/E ratio is 55.67x as of 2026-06-30.

What exchange does TEVA trade on?

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) trades on the NYSE, OTC.

Where is TEVA PHARMACEUTICAL INDUSTRIES LTD incorporated?

TEVA PHARMACEUTICAL INDUSTRIES LTD is incorporated in Israel.